Physician profile
Chebel A Khalil
NPI 1841400645
$71,778.39
in general payments reported to CMS, 2019-2025
21 companies · $40K in 2025
The $40K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.93 · 2020: $965 · 2021: $368 · 2022: $263 · 2023: $8,466 · 2024: $21K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Consulting Fee: $13K · Honoraria: $6,775 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,100 · Food and Beverage: $4,986 · Travel and Lodging: $4,267 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,100.00 |
| Consulting Fee | $12,700.00 |
| Honoraria | $6,775.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,100.00 |
| Food and Beverage | $4,985.94 |
| Travel and Lodging | $4,266.66 |
| Education | $164.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $38,686.99 | 2021-2025 | Krystexxa |
| Travere Therapeutics, INC. | $21,973.14 | 2023-2025 | Filspari |
| Horizon Therapeutics Plc | $8,399.45 | 2021-2023 | Krystexxa |
| Merit Medical Systems INC | $777.57 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $454.01 | 2019-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.41 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $169.14 | 2023-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $160.84 | 2022-2024 | Ultomiris |
| Bard Peripheral Vascular, INC. | $156.86 | 2020-2023 | Pristine |
| Bayer Healthcare Pharmaceuticals INC. | $152.08 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $100.89 | 2024-2025 | |
| Vifor Pharma, INC. | $97.50 | 2022-2023 | Korsuva, Veltassa |
| Ardelyx, INC. | $44.78 | 2024 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $39.15 | 2021 | |
| Baxter Healthcare | $26.98 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $24.99 | 2024 | Jynarque |
| Fresenius USA Marketing, INC. | $22.28 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $21.96 | 2024 | Crysvita |
| Opko Pharmaceuticals, LLC | $18.82 | 2025 | Rayaldee |
| Lilly USA, LLC | $15.80 | 2024 | Jardiance |
| Covidien LP | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chebel Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.